Session Information
Date: Sunday, November 8, 2026
Title: (0699-0705) Miscellaneous Rheumatic & Inflammatory Diseases Poster A
Session Type: Poster Session A
Session Time: 10:30AM-12:30PM
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that mimics malignancy, infection, and other autoimmune disorders. The most common organs involved are the major salivary glands, orbits and lacrimal glands, the pancreas, the kidneys, aorta and retroperitoneum, meninges, and thyroid gland. Because of its relatively recent recognition, its epidemiology and clinical manifestations in racially and ethnically diverse urban populations remain poorly described. This study aims to evaluate the clinical, serological, histopathological, and therapeutic features of patients with IgG4-RD within a multiracial tertiary care center in New York City.
Methods: We performed a retrospective chart review of patients aged >18 years diagnosed with IgG4-RD at an academic center between January 2012 and January 2022. Clinical, laboratory, and histopathological data were collected. Outcomes were categorized into remission (symptom-free >6 months), relapse, or persistent disease.
Results: Of the 20 patients identified with IgG4-RD, 2 were excluded due to a lack of biopsy data. Baseline demographic characteristics for the 18 patients were collected (Figure 1). The cohort consisted of 50% Hispanic, 38.9% African American, 5.6% White, and 5.6% Asian patients.
The head and neck were involved in 55.6% patients, Mikulicz’s disease seen in 38.9%, retroperitoneum/aorta involved in 27.8%, and pancreato-biliary system in 16.7%. Atypical manifestations included pachymeningitis (n=1) and coronary artery involvement (n=1). Serologically, 78% of patients had elevated serum IgG4 levels at diagnosis. Only 5 out of 18 patients (27.8%) met the 2019 ACR/EULAR classification criteria.
Clinical endpoints included persistent disease (n=1), relapse (n=6), and remission (n=11), with treatment correlations detailed in Figure 3. Glucocorticoids were initially started in 88.9% (n=16) of patients, and 72.2% (n=13) were on MMF, AZA, MTX or rituximab (RTX). Among those who relapsed, 50% (n=3) were on AZA or MTX and 50% (n=3) were on RTX. No statistically significant differences in organ involvement, laboratory markers, or relapse rates were observed across ethnic groups.
Conclusion: In this diverse cohort, Mikulicz’s disease presentation was common and serum IgG4 levels were not always elevated. While the disease is highly responsive to therapy, a third of patients experience relapses, even while on RTX maintenance therapy. Notably, the majority of clinically and pathologically confirmed cases did not meet the full 2019 ACR/EULAR classification criteria. This underscores that the ACR/EULAR criteria should serve as a classification tool rather than a strict diagnostic mandate; clinicians should not be discouraged from making the diagnosis in atypical or incomplete clinical scenarios.
Racial/ethnic demographics in the IgG4-RD cohort
Organ involvement vs relapse outcomes in the IgG4-RD cohort
Relapse outcomes in the different treatment groups in the IgG4-RD cohort
To cite this abstract in AMA style:
Mena Miranda O, Sanghavi N, Ayesha B. A Ten-Year Descriptive Study of IgG4-Related Disease at a Tertiary Care Center in New York City [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-ten-year-descriptive-study-of-igg4-related-disease-at-a-tertiary-care-center-in-new-york-city/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-ten-year-descriptive-study-of-igg4-related-disease-at-a-tertiary-care-center-in-new-york-city/
